keyboard_backspaceBack to listing
venture-img

Artelus

Medical Imaging

Artelus

Keywords:

Artelus, AI, Healthcare, Deep Learning, Forgotten Billion, Medical Data, Doctor-Assisted Solutions, Portable Devices, Cloud Computing, Early Warning Systems, Fatal Diseases, Diabetic Retinopathy, Vision Loss, LCHP-20, NFC-700, NFC-600, Hansanet, DRISTi, Sushruta, Nimi, Preventable Blindness, Bengaluru, Pittsburgh, Dubai, Healthcare Innovation, Medical Archives, Disease Diagnosis, Prognosis, Treatment, Global Health

SUMMARY

Artelus, an innovative company in the healthcare sector, focuses on using artificial intelligence (AI) and deep learning to assist in the early detection of diseases like Diabetic Retinopathy, TB, Breast cancer, and Lung cancer. Their commitment is to provide primary screening solutions that can help prevent these diseases from progressing, thus contributing significantly to global healthcare. The company's core product, DRISTi, is a Diabetic Retinopathy Screening tool designed to detect the early presence of Diabetic Retinopathy in patients. This AI product is notable for its ability to operate in remote areas without relying on the internet or cloud connectivity, offering point-of-care diagnostics to underserved populations. This approach is particularly crucial given that Diabetic Retinopathy affects a large portion of diabetic patients and is a leading cause of vision loss. Artelus stands out for its application of deep learning technology in healthcare. They utilize advanced methodologies such as self-supervised learning, DINO (Distillation of knowledge with NO labels), and BYOL (Bootstrap Your Own Latent) for training vision models. Additionally, they employ Generative Adversarial Networks (GANs) in diagnostic simulations to generate synthetic medical images, enhancing the diversity and accuracy of their AI models. The company's mission is to democratize healthcare for the "Forgotten Billion" by leveraging state-of-the-art Deep Learning architectures. This mission reflects their dedication to bridging global healthcare inequities and ensuring that even the most underserved populations have access to cutting-edge AI advancements.

PRODUCTS

DRISTi: An AI product for Diabetic Retinopathy Screening, operable in remote areas without internet dependency, Sushruta: AI-based Diabetic Retinopathy Screening System with high sensitivity and specificity, Nimi: AI product for identifying and segmenting regions of Diabetic Retinopathy in fundus images

SERVICES

Diagnostic AI Solutions, Healthcare Data Analysis, Collaborative Healthcare Projects, Custom AI Development for Healthcare

FOUNDER DETAILS
Pradeep Kumar Walia

over 20 years of experience in the IT industry, a Carnegie Mellon University alumnus

Rajarajeshwari Kodhandapani

Artelus

ABOUT

Artelus leverages AI for preventing blindness, focusing on accessible and innovative healthcare solutions.

COMPANY TYPE
Private / Independent
SERVICE VERTICALS
TECHNOLOGY
THERAPEUTIC AREAS
VALUE OFFERING
LOCATION

1665/A, 14th Main Rd, Sector 7, HSR Layout, Bengaluru, Karnataka 560102

TARGET USERS
  • HCP
  • Corporate
INCORPORATION DATE

February 8, 2016

STATE/CITY

Karnataka, Bengaluru

INDEX DATA USAGE NOTICE

At Mocero Health, we are committed to maintaining the trust and confidence of our visitors and users. This Index Data Usage Notice explains how we collect, use, and share data related to the various indices and aggregated metrics presented on our site. Index data on Mocero Health is generated through a combination of proprietary algorithms, user interactions, and publicly available health data. This may include, but is not limited to, health condition prevalence rates, treatment effectiveness scores, healthcare facility ratings, and user search trends. If you have concerns about how your data is used or wish to exercise your rights, please contact us at +91-9500115161. By using Mocero Health, you acknowledge and agree to the collection, use, and sharing of index data as described in this notice.

CONTENT DISCLAIMER

The information provided on this website is intended for general and educational purposes only. We reserve the right to modify this content policy at any time. Changes will be effective immediately upon posting the revised policy. Your continued use of the platform after any changes signifies your agreement to the new terms. If you have concerns about how your data is used or wish to exercise your rights, please contact us at +91-9500115161. By using this site, you acknowledge and agree that you have read and understood this Content Disclaimer.

News

Stay up-to-date with news about health-tech startups, compiled and presented in a centralized platform.